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tions of MMF. They demonstrated a signiﬁcant decrease in
grade II to IV GVHD in a small cohort of patients who
received extended administration; this study may provide
preliminary evidence of the potential differences in a longer
course of MMF [10].
MMF remains a well-tolerated and important immuno-
suppressive agent in our already limited arsenal of GVHD
prevention. Although newer and alternative GVHD prophy-
laxis regimens are certainly needed, the use of MMF should
not be abandoned until the optimal dosing and duration is
studied in larger prospective trials.
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We read with interest the report by Showel et al. [1] and
commentary by Gerber [2] describing the lack of a correla-
tion in some people between isolated clonal cytogenetic
abnormalities after autotransplant and leukemia recurrence.
The authors reasonably speculated this might be because
most subjects lacked abnormalities such as del(5/5q) or
del(7/7q), which alone might have been sufﬁcient to cause
acute myelogenous leukemia, because the clonalabnormalities occurred in only a fewmetaphases, suggesting
no proliferative advantage for the new clone and/or because
of brief follow-up.
The issue arises whether their observation applies only
to isolated clonal cytogenetic abnormalities or is a more
general phenomenon. We and others reported diverse
oligo- and polyclonal abnormalities in autotransplant
hrecipients, sometimes accompanied by nonclonal abnor-
malities, especially indels and aneuploidy. New trans-
locations are especially favored when ionizing radiation is
given pretransplant because of the tendency of photons to
cause synchronous and contiguous double-strand breaks in
interphase cells. These abnormalities can represent a sub-
stantial proportion of metaphases in some instances and
appear to wax and wane over many years, even decades.
Sometimes this is an illusion resulting from imperfect
sensitivity of our detection techniques. A study of 20
metaphases has a substantial likelihood of missing an
abnormality present in 5% to 10% of cells, for example. Also,
conventional cytogenetics capture only dividing cells;
ﬂorescence in situ hybridization can reduce this bias.
Sometimes these complex cytogenetic abnormities are a
harbinger of leukemia recurrence, although they may seem
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diagnosis. However, in other instances there is no leukemia
recurrence. Similar ﬁndings were reported in A-bomb sur-
vivors, their progeny, and radiation accident victims.
(Random, nonclonal abnormalities are even detected in
normal healthy persons, including neonates, when large
numbers of metaphases are studied.)
Because of the uncertain biological importance of
these cytogenetic abnormalities and because of limited
effective therapy options, physicians should refrain from
starting therapy until they are certain there is a high
probability of leukemia recurrence and until there are
convincing data early intervention produces a better
outcome than waiting for relapse. Whether the cytoge-
netic abnormalities we discuss are inherent to the original
leukemia or the result of exposing normal and/or leuke-
mia cells to DNA-damaging drugs and to ionizing radia-
tion, or both, cannot be presently determined but may bepossible using more sophisticated techniques such as
whole genome sequencing. However, one should consider
that sometimes a new mutation may cripple rather than
enable the leukemia clone(s) and need not eventuate in
relapse.
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